TRACON Pharmaceuticals (TCON) Touches $2.10 Low on Jun, 19; Realogy Group (H) Sentiment Is 2.15

June 19, 2017 - By Vivian Currie

The stock of TRACON Pharmaceuticals Inc (NASDAQ:TCON) reached all time low today, Jun, 19 and still has $2.02 target or 4.00% below today’s $2.10 share price. This indicates more downside for the $34.07 million company. This technical setup was reported by Barchart.com. If the $2.02 PT is reached, the company will be worth $1.36 million less. It is 0.00% or $0 reaching $2.1 per share. It is down 52.06% since June 19, 2016 and is downtrending. It has underperformed by 68.76% the S&P500.

Hyatt Hotels Corporation is a global hospitality company. The company has market cap of $7.33 billion. The Firm develops, owns, operates, manages, franchises, licenses or provides services to a portfolio of properties. It has a 32.1 P/E ratio. The Firm operates through four divisions: owned and leased hotels; Americas management and franchising ; ASPAC management and franchising (ASPAC), and EAME/SW Asia management and franchising (EAME/SW Asia).

Among 4 analysts covering Tracon Pharmaceuticals Inc (NASDAQ:TCON), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Tracon Pharmaceuticals Inc had 4 analyst reports since July 29, 2015 according to SRatingsIntel. The stock has “Buy” rating by Roth Capital on Wednesday, July 29. The stock of TRACON Pharmaceuticals Inc (NASDAQ:TCON) earned “Hold” rating by Zacks on Friday, September 4. Jefferies initiated TRACON Pharmaceuticals Inc (NASDAQ:TCON) rating on Wednesday, December 21. Jefferies has “Buy” rating and $10 target. As per Wednesday, July 29, the company rating was initiated by TH Capital.

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $34.07 million. The Firm is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases. It currently has negative earnings. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).

Grs Advisors Llc holds 8.05% of its portfolio in Hyatt Hotels Corporation for 238,692 shares. Long Pond Capital Lp owns 2.28 million shares or 5.9% of their US portfolio. Moreover, Glenhill Advisors Llc has 3% invested in the company for 766,606 shares. The New York-based Bamco Inc Ny has invested 1.42% in the stock. Gargoyle Investment Advisor L.L.C., a New Jersey-based fund reported 46,204 shares.

About 170,772 shares traded. Hyatt Hotels Corporation (H) has risen 27.49% since June 19, 2016 and is uptrending. It has outperformed by 10.79% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: